Shutdown: FDA will not accept submissions requiring fees until funding resumes
Regulatory NewsJoanne S. Eglovitch
Approval/marketing authorizationAudit/inspectionClinical TrialsComplianceGovernment/legislationMedical DevicesOTCPharmaceuticalsRegulatory Intelligence/PolicySubmission and registrationUnited StatesUS Food and Drug Administration (FDA)User fees